Nuvalent, Inc. NUVL
We take great care to ensure that the data presented and summarized in this overview for Nuvalent, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NUVL
View all-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.38 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$411 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$345 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$232 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$201 Million6.84% of portfolio
-
Commodore Capital LP New York, NY1.62MShares$124 Million12.71% of portfolio
-
State Street Corp Boston, MA1.49MShares$114 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA1.45MShares$111 Million30.59% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA1.32MShares$101 Million20.73% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.3MShares$99.5 Million0.01% of portfolio
Latest Institutional Activity in NUVL
Top Purchases
Top Sells
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at NUVL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-3.34%
|
$2,052,000
$76.06 P/Share
|
|
Mar 17
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$729,000
$27.85 P/Share
|
|
Mar 07
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-3.91%
|
$288,000
$72.13 P/Share
|
|
Mar 07
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+7.14%
|
$4,000
$1.08 P/Share
|
|
Mar 06
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
30,000
-14.18%
|
$2,130,000
$71.72 P/Share
|
|
Mar 06
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+16.61%
|
$90,000
$3.99 P/Share
|
|
Feb 24
2025
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.31%
|
$156,000
$78.38 P/Share
|
|
Feb 18
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-4.91%
|
$2,106,000
$78.73 P/Share
|
|
Feb 18
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$729,000
$27.85 P/Share
|
|
Jan 31
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,120
+4.71%
|
$0
$0.87 P/Share
|
|
Jan 27
2025
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.23%
|
$166,000
$83.51 P/Share
|
|
Jan 15
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-2.54%
|
$2,052,000
$76.1 P/Share
|
|
Jan 15
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$729,000
$27.85 P/Share
|
|
Jan 06
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,483
-1.34%
|
$196,157
$79.38 P/Share
|
|
Jan 06
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+23.09%
|
-
|
|
Jan 06
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,016
-2.63%
|
$317,264
$79.38 P/Share
|
|
Jan 06
2025
|
Darlene Noci Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+26.48%
|
-
|
|
Jan 06
2025
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,016
-2.05%
|
$317,264
$79.38 P/Share
|
|
Jan 06
2025
|
Christopher Durant Turner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+21.98%
|
-
|
|
Jan 06
2025
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,964
-1.93%
|
$234,156
$79.38 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 194K shares |
|---|---|
| Exercise of conversion of derivative security | 444K shares |
| Open market or private sale | 4.93M shares |
|---|